Anthropic reports Claude is used in six drug programs and its own preclinical efforts

AIAnthropic says it has deep research partnerships with six drug developers and has started its own drug discovery work, with Claude supporting multiple stages of development. Its in-house muscular dystrophy program could reach human trials as soon as late 2028, though the work is mostly preclinical.

Rohan Paul

@rohanpaul_ai

View on X

Anthropic now uses Claude inside real drug programs at 6 companies and runs its own, including muscular dystrophy work that could reach human trials as soon as late 2028.

Claude handled far more than molecule ideas: it generated roughly 35K antibody designs in about a month, coordinated 11 outside labs for a one-person biotech, and caught 7 manufacturing issues human reviewers missed.

The work remains mostly preclinical, though Anthropic’s in-house programs could put a drug into human trials as soon as late 2028.

Anthropic@AnthropicAI

Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own. In doing so, we’ve learned much more about how Claude can support the many stages of drug development. In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences. https://www.anthropic.com/research/early-progress-drug-development

View quoted post on X

Source details

Rohan Paul · x.comPublished Oct 27, 4:54 PM ET · added here 5:02 PM ET

Original title: > Anthropic now uses Claude inside real drug programs at 6 companies and runs its own, including muscular dystrophy work that could reach...

Anthropic reports Claude is used in six drug programs and its own preclinical efforts

Topics

Tags